Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02113163 · ClinicalTrials.gov registry record · Phase 1
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
A Phase 1 study of Hypertriglyceridemia and Diabetes Mellitus, Non-Insulin-Dependent, sponsored by Thetis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT02113163: Completed Phase 1 study of Hypertriglyceridemia and Diabetes Mellitus, Non-Insulin-Dependent, sponsored by Thetis Pharmaceuticals.
NCT02113163 is a Phase 1 study of Hypertriglyceridemia and Diabetes Mellitus, Non-Insulin-Dependent that has completed, run by Thetis Pharmaceuticals. The registered enrollment target is 32 participants, below the 175-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02113163, a Phase 1 study of Hypertriglyceridemia and Diabetes Mellitus, Non-Insulin-Dependent, has completed, sponsored by Thetis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the study is to contrast the pharmacokinetic profiles of metformin and EPA delivered separately as co-administered products (metformin hydrochloride or Glucophage and icosapent ethyl or Vascepa) and together as the solid dose form (metformin eicosapentaenoate or TP-101) under fasted and fed conditions. A secondary objective is to evaluate the safety and tolerability of single and repeat single doses of TP-101.
Conditions Studied
Interventions
- DRUG Metformin Eicosapentaenoate
- DRUG Metformin HCl and Vascepa
Study Locations (1)
Louisiana
- Pennington Biomedical Research Center - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
What the finished NCT02113163 record still lists
NCT02113163 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 175-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Metformin Eicosapentaenoate is the first listed.
NCT02113163 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT02113163 about?
NCT02113163 is a clinical study titled "PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA". The primary objective of the study is to contrast the pharmacokinetic profiles of metformin and EPA delivered separately as co-administered products (metformin hydrochloride or Glucophage and icosapent ethyl or Vascepa) and together as the solid dose form (metformin eicosapentaenoate or TP-101) unde...
What is the current status of trial NCT02113163?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2014-03. Estimated completion is 2014-07.
What conditions does trial NCT02113163 study?
This clinical trial studies the following conditions: Hypertriglyceridemia, Diabetes Mellitus, Non-Insulin-Dependent.
What interventions are being tested in trial NCT02113163?
The interventions under investigation include: Metformin Eicosapentaenoate (DRUG), Metformin HCl and Vascepa (DRUG).
Who is sponsoring clinical trial NCT02113163?
This trial is sponsored by Thetis Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02113163 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02113163's enrollment target sits among peer trials
32 17th of 25 higher than 9 of 25 other Hypertriglyceridemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertriglyceridemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
ACTIVE NOT RECRUITING · Phase 1
-
Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)
COMPLETED · Phase 1
-
Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals
COMPLETED · Phase 1
-
The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects
COMPLETED · Phase 1
-
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
COMPLETED · Phase 1
-
Study of Gemcabene in Adults With FPLD
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia